List view / Grid view

News

European experts meet with Afican regulators to discuss collaboration

10 March 2017 | By Steve Bremer, Managing Editor

Representatives from the European Medicines Agency (EMA) met with medicines regulators from Africa last week to discuss how to improve the availability of high quality, safe and effective medicines to patients in countries beyond Europe. One of the tools discussed was the scientific assessment of medicines or vaccines for use…

Head and neck cancer market fertile for investment

8 March 2017 | By GBI Research

A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, which could potentially transform the clinical and commercial landscape, according to business intelligence firm GBI Research.

Price drops make more cancer drugs routinely available

7 March 2017 | By Steve Bremer, Managing Editor

The National Institute for Health and Care Excellence (NICE) is half way through a review of drugs approved and still available only through the old Cancer Drugs Fund (CDF). In all cases so far where NICE has been able to make recommendations for routine NHS use, companies have reviewed and…

Watson-Marlow launches new bioprocessing pump technology at INTERPHEX 2017

7 March 2017 | By Watson-Marlow

Watson-Marlow Fluid Technology Group (WMFTG) the world leader in peristaltic pumps and associated fluid path technologies, will be unveiling a host of products at INTERPHEX 2017 including a new bioprocessing pump. Visitors to booth 2833 will witness a step change in tangential flow filtration (TFF), virus filtration (VF) and high-performance…

UK life sciences sector productivity double national average

7 March 2017 | By Steve Bremer, Managing Editor

The PwC report, commissioned by the Association of the British Pharmaceutical Industry (ABPI) and supported by the Association of the British Healthcare Industry (ABHI), the BioIndustry Association (BIA), and the British In Vitro Diagnostics Association (BIVDA), shows that the average productivity of UK life sciences employees, expressed as gross value…

AbbVie receives CHMP positive opinion for Hep C tablet combination

2 March 2017 | By Niamh Marriott, Digital Editor

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV)…